Growth factor receptors: promising drug targets in cancer

作     者：Snigdha Tiash Ezharul Hoque Chowdhury 

作者机构：Jeffrey Cheah School of Medicine and Health SciencesFaculty of MedicineNursing and Health SciencesMonash University46150 Bandar SunwaySelangorMalaysia 

出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)

年 卷 期：2015年第1卷第1期

页      面：190-200页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by a research grant(FRGS/2/2013/SG05/MUSM/02/2)of the Ministry of Higher Education(MOHE) Malaysia 

主　　题：Carbonate apatite nanoparticles growth factor receptor monoclonal antibodies protein kinase inhibitor short interfering RNA tyrosine kinase inhibitor 

摘      要：Genetic,epigenetic and somatic changes deregulate the expression of growth factor receptors(GFRs),leading to cancer initiation and *** cell growth and survival are orchestrated by clonal expansion and evasion of apoptotic signals in cancer *** growth of cells is further supported by angiogenesis and metastasis to distant *** expression of GFRs also contributes to the development of ***,therapeutics to target GFRs is a potentially attractive molecular approach to treat cancer more *** this review,we have discussed the contribution of GFRs to cancer development and addressed molecular approaches undertaken to inhibit GFR-mediated pathways.A wide number of monoclonal antibodies(mAbs)and protein kinase inhibitors targeting these GFR-mediated functions are in clinical trials to treat human ***,most drugs that target GFRs lead to the development of drug resistance and generate adverse *** acid-based therapeutics,*** interfering RNA(siRNA)could be harnessed to selectively silence GFR genes in cancer *** polymer,liposome-based nanocarriers,and the most recently developed pH-sensitive inorganic carbonate apatite nanoparticles have been used in cell culture and preclinical trials for cytoplasmic delivery of the siRNAs targeting different GFR ***-based therapeutics have been shown to have signifi cant potential to suppress GFR expression and functions and thus could be developed as molecular ***-targeting of tumors at different levels by combining various approaches along with chemotherapy would be a promising therapeutic approach to fight the *** nanocarriers capable of entrapping siRNA,mAb,GFR inhibitors and classical drugs targeting GFR have potential therapeutic applications.